Astrocytic Nrf2 expression protects spinal cord from oxidative stress following spinal cord injury in a male mouse model.
Astrocytes
Keap1
Nrf2
SCI
Spinal cord injury
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
06 Jun 2022
06 Jun 2022
Historique:
received:
03
11
2021
accepted:
21
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Spinal cord injury (SCI) induces a multitude of deleterious processes, including neuroinflammation and oxidative stress (OS) which contributed to neuronal damage and demyelination. Recent studies have suggested that increased formation of reactive oxygen species (ROS) and the consequent OS are critical events associated with SCI. However, there is still little information regarding the impact of these events on SCI. Astrocytes are key regulators of oxidative homeostasis in the CNS and astrocytic antioxidant responses promote the clearance of oxidants produced by neurons. Therefore, dysregulation of astrocyte physiology might largely contribute to oxidative damage. Nuclear factor erythroid 2-related factor 2 (Nrf2) is the main transcriptional regulator of cellular anti-oxidative stress responses. In the current study, we hypothesized that astrocytic activation of Nrf2 protects the spinal cord post injury via suppression of neuroinflammation. Thus, using mice line with a GFAP-specific kelch-like ECH-associated protein 1 (Keap1)-deletion, we induced a hyperactivation of Nrf2 in astrocytes and further its effects on SCI outcomes. SCI-induction was performed in mice using the Infinite Horizon Spinal Cord Impactor with a force of 60 kdyn. To assess the quantitative pattern of Nrf2/ARE-activation, we included transgenic ARE-Luc mice. Data were analyzed with GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA). Brown-Forsythe test was performed to test for equal variances and normal distribution was tested with Shapiro-Wilk. In ARE-Luc mice, a significant induction of luciferase-activity was observed as early as 1 day post-injury, indicating a functional role of Nrf2-activity at the epicenter of SCI. Furthermore, SCI induced loss of neurons and oligodendrocytes, demyelination and inflammation in wild type mice. The loss of myelin and oligodendrocytes was clearly reduced in Keap1 KO mice. In addition, Keap-1 KO mice showed a significantly better locomotor function and lower neuroinflammation responses compared to wild type mice. In summary, our in vivo bioluminescence data showed Nrf2-ARE activation during primary phase of SCI. Furthermore, we found that cell specific hyperactivation of Nrf2 was sufficient to protect the spinal cord against injury which indicate a promising therapeutic approach for SCI-treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Spinal cord injury (SCI) induces a multitude of deleterious processes, including neuroinflammation and oxidative stress (OS) which contributed to neuronal damage and demyelination. Recent studies have suggested that increased formation of reactive oxygen species (ROS) and the consequent OS are critical events associated with SCI. However, there is still little information regarding the impact of these events on SCI. Astrocytes are key regulators of oxidative homeostasis in the CNS and astrocytic antioxidant responses promote the clearance of oxidants produced by neurons. Therefore, dysregulation of astrocyte physiology might largely contribute to oxidative damage. Nuclear factor erythroid 2-related factor 2 (Nrf2) is the main transcriptional regulator of cellular anti-oxidative stress responses.
METHODS
METHODS
In the current study, we hypothesized that astrocytic activation of Nrf2 protects the spinal cord post injury via suppression of neuroinflammation. Thus, using mice line with a GFAP-specific kelch-like ECH-associated protein 1 (Keap1)-deletion, we induced a hyperactivation of Nrf2 in astrocytes and further its effects on SCI outcomes. SCI-induction was performed in mice using the Infinite Horizon Spinal Cord Impactor with a force of 60 kdyn. To assess the quantitative pattern of Nrf2/ARE-activation, we included transgenic ARE-Luc mice. Data were analyzed with GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA). Brown-Forsythe test was performed to test for equal variances and normal distribution was tested with Shapiro-Wilk.
RESULTS
RESULTS
In ARE-Luc mice, a significant induction of luciferase-activity was observed as early as 1 day post-injury, indicating a functional role of Nrf2-activity at the epicenter of SCI. Furthermore, SCI induced loss of neurons and oligodendrocytes, demyelination and inflammation in wild type mice. The loss of myelin and oligodendrocytes was clearly reduced in Keap1 KO mice. In addition, Keap-1 KO mice showed a significantly better locomotor function and lower neuroinflammation responses compared to wild type mice.
CONCLUSIONS
CONCLUSIONS
In summary, our in vivo bioluminescence data showed Nrf2-ARE activation during primary phase of SCI. Furthermore, we found that cell specific hyperactivation of Nrf2 was sufficient to protect the spinal cord against injury which indicate a promising therapeutic approach for SCI-treatment.
Identifiants
pubmed: 35668451
doi: 10.1186/s12974-022-02491-1
pii: 10.1186/s12974-022-02491-1
pmc: PMC9169394
doi:
Substances chimiques
Kelch-Like ECH-Associated Protein 1
0
NF-E2-Related Factor 2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134Subventions
Organisme : China Scholarship Council
ID : 20190808157
Informations de copyright
© 2022. The Author(s).
Références
J Biol Chem. 2015 Sep 11;290(37):22805-17
pubmed: 26231211
J Clin Invest. 1993 Jul;92(1):349-58
pubmed: 8326003
Redox Biol. 2020 Sep;36:101644
pubmed: 32863210
Clin Sci (Lond). 2015 Dec;129(12):989-99
pubmed: 26386022
Biochim Biophys Acta Mol Cell Res. 2018 May;1865(5):721-733
pubmed: 29499228
Arch Phys Med Rehabil. 2001 Sep;82(9):1181-7
pubmed: 11552188
Redox Biol. 2017 Apr;11:613-619
pubmed: 28110218
J Biochem Mol Biol. 2004 Mar 31;37(2):139-43
pubmed: 15469687
J Neurosci. 2006 Jul 26;26(30):7849-59
pubmed: 16870730
World Allergy Organ J. 2012 Jan;5(1):9-19
pubmed: 23268465
Nat Rev Mol Cell Biol. 2020 Jul;21(7):363-383
pubmed: 32231263
Cell Prolif. 2020 Mar;53(3):e12781
pubmed: 32035016
Exp Neurol. 1996 Jun;139(2):244-56
pubmed: 8654527
Biol Sex Differ. 2020 Mar 29;11(1):12
pubmed: 32223745
Aging Dis. 2019 Jun 01;10(3):637-651
pubmed: 31165007
J Neurosurg. 2002 Jul;97(1 Suppl):142-7
pubmed: 12120639
Physiol Rev. 2014 Apr;94(2):329-54
pubmed: 24692350
Glia. 1999 Nov;28(2):85-96
pubmed: 10533053
Biochem Biophys Res Commun. 1997 Jul 18;236(2):313-22
pubmed: 9240432
Eur J Neurosci. 2002 Nov;16(9):1731-40
pubmed: 12431226
Nat Rev Neurosci. 2006 Mar;7(3):194-206
pubmed: 16495941
Brain Res. 2000 Nov 17;883(2):165-77
pubmed: 11074045
Oxid Med Cell Longev. 2016;2016:1245049
pubmed: 27478531
Spinal Cord. 2000 Dec;38(12):717-23
pubmed: 11175370
Exp Neurol. 2008 Feb;209(2):294-301
pubmed: 17617407
Pharmacol Ther. 2016 Jan;157:84-104
pubmed: 26617217
J Neurotrauma. 2017 Nov 1;34(21):3027-3040
pubmed: 27889959
Spinal Cord. 2006 Mar;44(3):182-7
pubmed: 16130019
Neonatology. 2008;93(2):125-31
pubmed: 17785990
J Neurotrauma. 2005 Mar;22(3):368-81
pubmed: 15785232
J Med Food. 2021 Mar;24(3):218-225
pubmed: 33739882
Nat Rev Neurosci. 2015 May;16(5):249-63
pubmed: 25891508
Nat Rev Neurosci. 2004 Feb;5(2):146-56
pubmed: 14735117
Physiol Rev. 2019 Jan 1;99(1):21-78
pubmed: 30280653
Spine J. 2016 Nov;16(11):1392-1403
pubmed: 27349631
Nat Commun. 2016 May 23;7:11624
pubmed: 27211851
Nat Rev Neurosci. 2006 Aug;7(8):628-43
pubmed: 16858391
Arthritis Res Ther. 2012 Oct 27;14(5):R220
pubmed: 23072510
Plant Cell. 2005 Jul;17(7):1866-75
pubmed: 15987996
Spinal Cord. 2012 Apr;50(4):264-74
pubmed: 21987065
J Neurotrauma. 2006 May;23(5):635-59
pubmed: 16689667
Glia. 2016 Dec;64(12):2219-2230
pubmed: 27641725
Dialogues Clin Neurosci. 2009;11(3):281-95
pubmed: 19877496
Biochim Biophys Acta. 2012 May;1822(5):675-84
pubmed: 22080976
Brain. 2011 Mar;134(Pt 3):678-92
pubmed: 21354971
J Pharmacol Sci. 2020 Jul;143(3):209-218
pubmed: 32414692
Oxid Med Cell Longev. 2019 Oct 13;2019:5080843
pubmed: 31737171
Neural Regen Res. 2014 Nov 15;9(22):2008-12
pubmed: 25598784
Eur J Pharmacol. 2021 Mar 15;895:173878
pubmed: 33453223
Acta Biochim Pol. 2016;63(3):589-93
pubmed: 27474401
Mol Cell Biol. 2004 Oct;24(19):8477-86
pubmed: 15367669
J Clin Biochem Nutr. 2014 May;54(3):151-60
pubmed: 24895477
Cell Mol Life Sci. 2016 Sep;73(17):3221-47
pubmed: 27100828
J Neurosci. 2004 Feb 4;24(5):1101-12
pubmed: 14762128
Biochemistry (Mosc). 2013 Feb;78(2):111-26
pubmed: 23581983
Front Neurol. 2019 Mar 22;10:282
pubmed: 30967837
J Neurotrauma. 2002 Feb;19(2):175-90
pubmed: 11893021
Toxicol Mech Methods. 2021 Jun;31(5):334-342
pubmed: 33627030
Life Sci. 2020 Mar 15;245:117351
pubmed: 31981629
Science. 2011 Jul 8;333(6039):238-42
pubmed: 21737741